YOTTA CAPITAL & OUEST CROISSANCE take majority stake in Les Laboratoires Herbolistique

Zimmer Biomet acquires Monogram Technologies, an AI-driven orthopedic robotics company, to strengthen its leadership position in the fast-growing orthopedic surgical robotics segment. The transaction, closed in October 2025, integrates Monogram's semi-autonomous and fully autonomous technologies into Zimmer Biomet's existing portfolio. The strategic logic rests on several drivers. First, Monogram's CT-based technology complements Zimmer Biomet's ROSA platform, which uses an imageless approach, enabling the group to address diverse surgeon preferences in surgical techniques (with or without CT, robotic or non-robotic, manual or autonomous)

Teledyne's acquisition of Varex creates a fully integrated component supplier across medical imaging and industrial inspection markets. The transaction directly addresses a structural gap in Teledyne's portfolio: while it previously manufactured low-dose CMOS sensors for dental uses and magnetrons for radiotherapy machines, it lacked in-house X-ray tube production for hospital CT scanners and fluoroscopy units. Key strategic drivers include: (1) Direct Portfolio Fit: Teledyne secures high-output X-ray tube engineering, radiation-hardened detectors for oncology, and next-generation photon-counting sensor technology

Bain Capital acquires Vitabiotics, the UK's largest vitamin company, in a transaction that marks a significant milestone in the family business's 55-year history. The operation, announced in July 2026, combines the expertise of a global healthcare and consumer investor with an internationally recognized platform of vitamins, minerals, and supplements brands. The UK remains central to Vitabiotics' brand, innovation, and category leadership. The investment will be led by Bain Capital's Asia Private Equity team, bringing local knowledge of Indian and Asian markets where Vitabiotics has already established leading positions

DHCare has entered into an agreement to acquire Ottobock's Human Mobility business, which specializes in manual and power wheelchairs, as well as pediatric mobility solutions. This transaction is part of Ottobock's strategy to refocus its resources on its core, high-growth businesses, including prosthetics, neuro-orthotics, and exoskeletons. The divested business generates approximately €80 million in annual revenue, employs around 270 staff members, and comprises the German Human Mobility companies, as well as veldink4Kids, a Dutch specialist in pediatric wheelchairs

Obagi Medical, a medical-grade skincare company positioned in the professional dermatology and aesthetics segment, is being acquired by Bridgepoint as part of a broader consolidation trend across clinical skincare markets. The transaction reflects a strategy focused on building specialised platforms within dermatology and aesthetics, supported by structural growth driven by the medicalisation of skincare routines and the convergence of beauty and healthcare. Bridgepoint aims to build an integrated platform of clinical skincare and aesthetics brands covering a broader spectrum of solutions, from dermatological treatments to injectable aesthetic products

CordenPharma, backed by private equity firm Astorg, entered into an agreement to acquire AmbioPharm, a US-based CDMO specializing in complex peptide APIs with manufacturing sites in the United States and China. The transaction is part of CordenPharma’s broader strategy to strengthen its position as a global leader in peptide therapeutics manufacturing, a high-growth segment driven by next-generation pharmaceutical innovation, including GLP-1 and other advanced peptide-based therapies. The acquisition adds complementary capabilities across solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), hybrid synthesis technologies, as well as downstream purification and lyophilization capacities

The acquisition of a 51% controlling interest in Laboratoire Nutergia by 3i presents a primary leveraged buyout transaction designed to transition a mature, founder-led enterprise into an institutionalized platform capable of capturing pan-European market share. Following a competitive auction process managed by financial advisor Houlihan Lokey involving several leading private equity sponsors, 3i secured the transaction by leveraging its institutional heritage in consumer healthcare and demonstrating complete strategic alignment with the founding Lagarde family, who will retain a 49% minority stake and remain active corporate stewards

The closing of this oversubscribed 86.6 million dollar Series B financing represents a structural capitalization event designed to transition Ona Therapeutics into a clinical-stage oncology platform and fund operations through its primary clinical data readouts. This institutional funding round replaces early-stage venture capital with a deep-pocketed, clinically-focused investment syndicate capable of supporting the high cash-burn rate associated with executing Phase I/II clinical trials for lead program ONA-255 in breast cancer patients

The transaction involves the all-cash acquisition of Apogee Therapeutics by AbbVie, as part of a strategic move to bolster AbbVie's immunology portfolio, particularly in the area of chronic inflammatory diseases with significant unmet medical needs. Apogee Therapeutics has developed a monoclonal antibody targeting interleukin-13, which has the potential to treat atopic dermatitis and other inflammatory conditions. The strategic rationale is also driven by the complementary nature of Apogee's assets with AbbVie's existing immunology portfolio, including its established treatments for inflammatory diseases

Motion Equity Partners has acquired a majority stake in Polaris, a leading manufacturer of omega-3 concentrates, from Demea Agro, which had invested in the company three years ago. This transaction is part of a broader strategy to drive external growth and international expansion, with ambitious plans to establish a US-based industrial site and double in size within the next five years. Historical shareholders of Polaris, including Cerea Partners, Seventure, and Picama, are reinvesting alongside Motion Equity Partners, which brings its expertise in supporting industrial companies in their international development